Cargando…
Magnetic Resonance Spectroscopy: An In Vivo Molecular Imaging Biomarker for Parkinson's Disease?
Parkinson's disease (PD) is a neurodegenerative disorder caused by selective loss of dopaminergic neurons in the substantia nigra pars compacta which leads to dysfunction of cerebral pathways critical for the control of movements. The diagnosis of PD is based on motor symptoms, such as bradykin...
Autores principales: | Ciurleo, Rosella, Di Lorenzo, Giuseppe, Bramanti, Placido, Marino, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180390/ https://www.ncbi.nlm.nih.gov/pubmed/25302300 http://dx.doi.org/10.1155/2014/519816 |
Ejemplares similares
-
Magnetic resonance imaging markers for early diagnosis of Parkinson's disease☆
por: Marino, Silvia, et al.
Publicado: (2012) -
Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study
por: Bonanno, Lilla, et al.
Publicado: (2022) -
The impact of SARS-COV2 infection on people in residential care with Parkinson Disease or parkinsonisms: Clinical case series study
por: Sorbera, Chiara, et al.
Publicado: (2021) -
The effect on deep brain stimulation of subthalamic nucleus and dopaminergic treatment in Parkinson disease
por: Lo Buono, Viviana, et al.
Publicado: (2020) -
Anxiety, depression, and quality of life in Parkinson’s disease: the implications of multidisciplinary treatment
por: Lo Buono, Viviana, et al.
Publicado: (2020)